A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials show the new formulation improves the drug's effectiveness by 40 per cent.
from Top Health News -- ScienceDaily https://ift.tt/317n7A4
No comments:
Post a Comment